Diabetes-Focused Insulet Forecasts Strong 2026 Growth, Stock Soars

Core Viewpoint - Insulet Corporation reported better-than-expected fourth-quarter earnings and provided optimistic guidance for 2026, leading to a rise in stock price [1] Financial Performance - Fourth-quarter adjusted earnings reached $1.55 per share, surpassing the consensus estimate of $1.45 [1] - Sales for the quarter were $783.8 million, reflecting a year-over-year increase of 31.2% or 29% in constant currency, exceeding the consensus of $768.69 million [2] - Total Omnipod revenue was $781.8 million, up 33.5% year-over-year or 31.3% in constant currency [2] - Gross margin improved to 72.5%, an increase of 40 basis points from the prior year [3] - Operating income was $146.3 million, representing 18.7% of revenue, also up 40 basis points year-over-year [3] Share Buyback - The board approved a $350 million increase in share repurchase authorization, with plans to allocate approximately $300 million toward repurchases in the first quarter of 2026 [4] 2026 Guidance - Insulet forecasts fiscal 2026 sales between $3.250 billion and $3.304 billion, indicating a year-over-year growth of 20%-22% [5] - The guidance includes total Omnipod Products growth projected between 21%-23% [5] - Adjusted operating margin is expected to expand by approximately 100 basis points, with adjusted earnings per share anticipated to grow by over 25% [6] - First-quarter 2026 sales are expected to be between $705.5 million and $716.94 million, compared to the consensus of $713.41 million [6]